Last reviewed · How we verify
PD-1 inhibitors plus lenvatinib — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
PD-1 inhibitors plus lenvatinib (PD-1 inhibitors plus lenvatinib) — Chen Xiaoping.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PD-1 inhibitors plus lenvatinib TARGET | PD-1 inhibitors plus lenvatinib | Chen Xiaoping | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PD-1 inhibitors plus lenvatinib CI watch — RSS
- PD-1 inhibitors plus lenvatinib CI watch — Atom
- PD-1 inhibitors plus lenvatinib CI watch — JSON
- PD-1 inhibitors plus lenvatinib alone — RSS
Cite this brief
Drug Landscape (2026). PD-1 inhibitors plus lenvatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/pd-1-inhibitors-plus-lenvatinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab